Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer

24 Jun 2020

Abstract excerpt

BACKGROUND: The ERG oncogene, a member of the ETS family of transcription factor encoding genes, is a genetic driver of prostate cancer. It is activated through a fusion with the androgen-responsive TMPRSS2 promoter in 50% of cases. There is therefore significant interest in developing novel therapeutic agents that target ERG. We have taken an antisense approach and designed morpholino-based oligonucleotides that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Prostate Cancer Diagnosis and Treatment
Share to Prostate Cancer Treatment and Research
Share to Wnt/β-catenin signaling in development and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32581342
DOI: 10.1038/s41416-020-0951-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancerPMID 32581342Read ↗

Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancerSemantic proximity Read ↗

Quantitative Analysis of ERG Expression and Its Splice Isoforms in Formalin-Fixed, Paraffin-Embedded Prostate Cancer SamplesSemantic proximity Read ↗

Significance of the TMPRSS2:ERG gene fusion in prostate cancer.Semantic proximity Read ↗

Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell GrowthSemantic proximity Read ↗

5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer.Semantic proximity Read ↗

Pleiotropic Biological Activities of Alternatively Spliced TMPRSS2/ERG Fusion Gene TranscriptsSemantic proximity Read ↗

Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer.Semantic proximity Read ↗

YK-4-279 Inhibits ERG and ETV1 Mediated Prostate Cancer Cell InvasionSemantic proximity Read ↗

Delineation of <i>TMPRSS2-ERG</i> Splice Variants in Prostate CancerSemantic proximity Read ↗

Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG‐positive prostate cancerSemantic proximity Read ↗

Novel RNA Hybridization Method for the In Situ Detection of ETV1, ETV4, and ETV5 Gene Fusions in Prostate CancerSemantic proximity Read ↗

Targeted Radiosensitization of ETS Fusion-Positive Prostate Cancer through PARP1 InhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.